文献速递腹部CTMR

肌少症是胰腺癌患者独立预后因素:一项Meta分析

Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer - a Meta-analysis.
PubMed 文献 · Acad Radiol · 2022-12-22

该系统综述纳入22项研究共3958例胰腺导管腺癌患者,旨在明确肌少症对治愈性和姑息性治疗背景下相关结局的影响。肌少症患病率为38.7%,在姑息治疗背景下更常见;肌少症与治愈性和姑息性背景下更差的总生存期均独立相关,但与术后并发症无关。

要点

  • 肌少症在胰腺癌患者中患病率为38.7%,姑息治疗背景下更常见。
  • 肌少症是胰腺癌患者总生存期较差的独立预后因素。
  • 肌少症与术后并发症发生率无关。

关键影像表现/征象

  • 肌少症定义为骨骼肌丢失,可通过横断面影像评估。
  • 肌少症在姑息治疗背景下的患病率高于治愈性背景。

诊断标准与关键数值

  • 治愈性背景下,单变量分析中肌少症与更差总生存期相关(HR 1.79,95%CI 1.41-2.28,p<0.001)。
  • 治愈性背景下,多变量分析中肌少症与更差总生存期相关(HR 1.62,95%CI 1.27-2.07,p<0.001)。
  • 姑息性背景下,单变量分析中肌少症与总生存期相关(HR 1.56,95%CI 1.21-2.02,p<0.001)。
  • 姑息性背景下,多变量分析中肌少症与总生存期相关(HR 1.77,95%CI 1.39-2.26,p<0.001)。
  • 单变量分析中肌少症与术后并发症发生率无关(OR 1.10,95%CI 0.70-1.72,p=0.69)。

临床应用与阅片要点

  • 在胰腺癌患者影像报告中评估肌少症有助于预后分层。
  • 肌少症评估应纳入个体化肿瘤治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Sarcopenia is defined as skeletal muscle loss and can be assessed by cross-sectional imaging. Our aim was to establish the effect of sarcopenia on relevant outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) in curative and palliative settings based on a large patient sample.

MATERIALS AND METHODS: MEDLINE library, EMBASE and SCOPUS databases were screened for the associations between sarcopenia and mortality in patients with PDAC up to March 2022. The primary endpoint of the systematic review was the hazard ratio of Sarcopenia on survival. 22 studies were included into the present analysis.

RESULTS: The included 22 studies comprised 3958 patients. The prevalence of sarcopenia was 38.7%. Sarcopenia was associated with a higher prevalence in the palliative setting (OR 53.23, CI 39.00-67.45, p<0.001) compared to the curative setting (OR 36.73, CI 27.81-45.65, p<0.001). Sarcopenia was associated with worse OS in the univariable (HR 1.79, CI 1.41-2.28, p<0.001) and multivariable analysis (HR 1.62, CI 1.27-2.07, p<0.001) in the curative setting. For the palliative setting the pooled hazards ratio showed that sarcopenia was associated with overall survival (HR 1.56, CI 1.21-2.02, p<0.001) as well as in multivariable analysis (HR 1.77, CI 1.39-2.26, p<0.001). Sarcopenia was not associated with a higher rate of post-operative complications in univariable analysis (OR 1.10, CI 0.70-1.72, p = 0.69).

CONCLUSION: Sarcopenia occurs in 38.7% of patients with pancreatic cancer, significantly more in the palliative setting. Sarcopenia is associated with overall survival in both settings. The assessment of sarcopenia is therefore relevant for personalized oncology. Sarcopenia is not associated with postoperative complications.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Thormann, Hinnerichs, Barajas Ordonez, et al. Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer - a Meta-analysis. Acad Radiol. 2022. PMID: 36564257. doi:10.1016/j.acra.2022.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。